Sign In
Buy PTC
$139.72
-2.62 (-1.84%)
At Close: Jun 03, 2026
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
04:01pm, Thursday, 07'th Nov 2024
– Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million – – Regulatory filings for sepiapterin, Translarna™ and AADC gene therapy under review by
PTC's Q4 Earnings Surpass Estimates, Revenues Rise Y/Y, Shares Jump
09:35am, Thursday, 07'th Nov 2024
PTC's Q4 performance is driven by steady growth in recurring revenues amid a tough sales backdrop.
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
10:18pm, Wednesday, 06'th Nov 2024
PTC Inc. (PTC) Q4 2024 Earnings Call Transcript
Compared to Estimates, PTC Inc. (PTC) Q4 Earnings: A Look at Key Metrics
07:36pm, Wednesday, 06'th Nov 2024
Although the revenue and EPS for PTC Inc. (PTC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Str
PTC Inc. (PTC) Q4 Earnings and Revenues Beat Estimates
06:21pm, Wednesday, 06'th Nov 2024
PTC Inc. (PTC) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.20 per share a year ago.
PTC forecasts quarterly revenue below estimates on tight tech spending
05:57pm, Wednesday, 06'th Nov 2024
Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design and testing software as companies keep a tig
PTC ANNOUNCES $2 BILLION SHARE REPURCHASE AUTHORIZATION
04:01pm, Wednesday, 06'th Nov 2024
BOSTON , Nov. 6, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that its Board of Directors has authorized the repurchase of up to $2 billion worth of PTC common stock through September 30, 2
PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2024 RESULTS
04:01pm, Wednesday, 06'th Nov 2024
Solid ARR and Cash Flow in Fourth Fiscal Quarter and Full Fiscal Year BOSTON , Nov. 6, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full f
PTC to Report Q4 Earnings: Here's What Investors Should Know
09:45am, Tuesday, 05'th Nov 2024
PTC's fiscal fourth-quarter performance is likely to have been driven by strong business momentum across PLM and CAD segments amid forex fluctuations.
PTC Therapeutics to Participate at Upcoming Investor Conferences
04:30pm, Monday, 04'th Nov 2024
WARREN, N.J. , Nov. 4, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: UBS Global Healthcare C
PTC Inc. (PTC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Friday, 01'st Nov 2024
Evaluate the expected performance of PTC Inc. (PTC) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric
PTC Inc. (PTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Wednesday, 30'th Oct 2024
PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vishay Intertechnology High Energy Inrush Current Limiting PTC Thermistors Increase Performance in Active Charge and Discharge Circuits
11:00am, Wednesday, 30'th Oct 2024
Reducing Component Counts, Self-Protecting Devices Combine Energy Handling to 340 J With R25 Values to 1.5 kΩ and High Voltages to 1200 VDC Reducing Component Counts, Self-Protecting Devices Combine
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
07:00am, Wednesday, 30'th Oct 2024
WARREN, N.J. , Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 25'th Oct 2024
WARREN, N.J. , Oct. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an aggregate of 1
